Watson Biotech (300142): Terminates clinical trial of recombinant new coronavirus vaccine (chimpanzee adenovirus vector) – CFi.CN China Finance Network

Original title: Watson Bio: Announcement on the termination of clinical trials of recombinant new coronavirus vaccine (chimpanzee adenovirus vector)

Securities code: 300142 Securities abbreviation: Watson Biotechnology Announcement Number: 2024-034 Yunnan Watson Biotechnology Co., Ltd.
Regarding the termination of clinical trials of recombinant novel coronavirus vaccine (chimpanzee adenovirus vector)
Announcement of the trial
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions. After deliberation and approval at the third meeting of the 2024 President’s Office Meeting of Yunnan Watson Biotechnology Co., Ltd. (hereinafter referred to as the “Company”), it was decided to terminate the wholly-owned subsidiary Beijing Weida Biotechnology Co., Ltd. (hereinafter referred to as “Beijing Weida” ) Clinical trials of the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector) developed by The recombinant new coronavirus vaccine (chimpanzee adenovirus vector) received the “Drug Clinical Trial Approval” approved by the State Food and Drug Administration in May 2021. Approval number: 2021L90009, registration classification: preventive biological products. After obtaining the clinical trial approval, the company, Beijing Weida and relevant partners formulated a detailed clinical trial plan for the clinical research of this vaccine and carried out Phase I and Phase II clinical research of this vaccine.

This vaccine is mainly used to prevent new coronavirus disease caused by SARS-CoV-2 infection
(COVID-19). Due to the early start of research and development, this vaccine was mainly designed and developed for the antigen of the prototype strain of the new coronavirus that was prevalent at the time. According to the mutation of the new coronavirus, this vaccine now does not meet the current national requirements for the new coronavirus vaccine to contain XBB mutant strains or be effective against XBB mutant strains. The economic and social benefits of continuing to develop this vaccine are low, so the company The decision was made to terminate clinical trials of a recombinant novel coronavirus vaccine (chimpanzee adenovirus vector).

The termination of the clinical trial of this vaccine will not affect the company’s continued layout of the adenovirus vector technology platform. The company will continue to pay attention to the development trends of the industry and new technologies, and based on its existing technology accumulation, it will choose other blockbuster vaccine varieties for research and development. , continue to build the company’s adenovirus vector technology platform, and the company will fulfill its information disclosure obligations in accordance with laws, regulations and normative documents regarding subsequent relevant progress.

The termination of the clinical trial of the vaccine will not have an impact on the company’s daily production operations and the research and development of other ongoing projects, nor will it have a significant impact on the company’s performance this year. Investors are advised to make prudent decisions and pay attention to investment risks.

Special announcement.

Yunnan Watson Biotechnology Co., Ltd.
Board of Directors
April 25, 2024

China Finance Network